Melanoma Immunotherapy Slows Tumor Growth and Improves Survival in Mice
the Cancer Therapy Advisor take:
A new DNA-based cancer immunotherapy that targets melanoma has induced large immune response in animal models and was effective at directing T-cells to attack tumor cells, a study by Inovio Pharmaceuticals, Inc. that was published in the journal Cancer Gene Therapy has found.
For the study, researchers at the company designed a synthetic DNA immunotherapy that encodes the tyrosinase gene. This gene is overexpressed in about 80% of melanoma cells. They found that when tested in mice, the immunotherapy was able to infiltrate the tumor site, prevented more tumors, slowed tumor growth, and altered the tumor by blocking cells that inhibit T-cell activity.
They also found that when compared to mice in a control group, mice who received the DNA immunotherapy had an increased survival.
Inovio Pharmaceuticals, Inc. is also developing and studying other immunotherapies for various cancer types, including breast, cervical, head and neck, lung, and pancreatic.
According to the American Cancer Society (ACS), about 76,100 patients will be diagnosed with melanoma in 2014 and about 9,710 are expected to die as a result of the disease. ACS also estimates that the 5-year survival rate of those with stage 3 or 4 melanoma is 15%.
A new DNA-based cancer immunotherapy that targets melanoma has induced large immune response.
In this study, Inovio developed a synthetic DNA immunotherapy encoding the tyrosinase gene which is highly expressed in nearly 80% of melanoma tumor cells. Researchers found in mice that the tyrosinase-targeting DNA immunotherapy was very effective in infiltrating the tumor site, where it prevented tumors, controlled tumor growth, and changed the tumor micro-environment by "turning off" cells that suppress T-cell activity. Inovio's therapy also increased survival in melanoma-challenged mice versus a control group.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer